[Retracted] Significance of the Expression of TC and TG Levels in the Initial Diagnosis and Treatment of SCLC Patients and Their Tie-In with Prognosis

Table 2

Univariate analysis of clinical data differences in the prognosis of SCLC patients with progression-free survival time.

Index		PFS (months)	t	P
Gender	Male (n = 62)	9.85 ± 1.23	−0.957	0.341
	Female (n = 28)	10.12 ± 1.26
Age	>65 years old (n = 31)	9.89 ± 1.32	−0.236	0.814
	≤65 years old (n = 59)	9.96 ± 1.35
Tumor stage	Limited period (n = 51)	12.59 ± 1.63	16.607	<0.001
	Extensive period (n = 39)	7.33 ± 1.28
Distant metastasis	Yes (n = 21)	10.59 ± 1.57	−1.654	0.102
	No (n = 69)	11.19 ± 1.42
Lymph node metastasis	Yes (n = 25)	8.99 ± 1.26	−1.847	0.068
	No (n = 65)	9.56 ± 1.33
BIM classification	<18.5 kg/m^2 (n = 20)	6.73 ± 1.02	−1.632	0.106
	18.5∼24.9 kg/m^2 (n = 33)	10.69 ± 1.42
	>24.9 kg/m^2 (n = 37)	8.23 ± 1.34
Smoking status	Yes (n = 62)	9.55 ± 1.36	−1.157	0.250
	No (n = 28)	9.91 ± 1.38
HDL-C	<1.0 mmol/l (n = 42)	9.89 ± 1.42	1.286	0.202
	≥1.0 mmol/l (n = 48)	9.51 ± 1.38
TC	>5.5 mmol/L (n = 47)	7.52 ± 1.15	−16.545	<0.001
	≤5.5 mmol/l (n = 43)	12.33 ± 1.59
TG	>1.7 mmol/L (n = 39)	12.95 ± 1.69	23.209	<0.001
	≤1.7 mmol/l (n = 51)	6.13 ± 1.09
Operation	Yes (n = 62)	10.15 ± 1.48	1.441	0.153
	No (n = 28)	9.68 ± 1.32
Radiotherapy	Yes (n = 65)	10.25 ± 1.52	1.939	0.056
	No (n = 25)	9.56 ± 1.49